Mai Capital Management Esperion Therapeutics, Inc. Transaction History
Mai Capital Management
- $13 Billion
- Q1 2025
A detailed history of Mai Capital Management transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Mai Capital Management holds 30 shares of ESPR stock, worth $24. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30
Previous 30
-0.0%
Holding current value
$24
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
200Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$11.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$9.53 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$9.07 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$8.05 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$5.75 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $55.2M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...